UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight on Portfolio Quality
Morgan Stanley initiated coverage on NPS Pharmaceuticals (NASDAQ: NPSP) with an Overweight rating and a $17 price target
Morgan Stanley commented, "NPS has two novel, late stage assets that we believe have key characteristics that to us indicate a high chance of commercial success despite the increasingly difficult reimbursement environment: a) strong efficacy and safety with a good disease impact, b) target diseases with a high unmet need and high acuity, and c) a competitive/unique drug profile. We believe the Street undervalues these novel assets, removing the long term leverage from this focused, orphan model."
NPS Pharmaceuticals closed at $9.52 on Wednesday.
Latest Ratings for NPSP
|Jan 2015||JP Morgan||Maintains||Neutral|
|Jan 2015||Canaccord Genuity||Downgrades||Buy||Hold|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.